XML 15 R24.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue and Contract Acquisition Costs (Tables)
9 Months Ended
Sep. 30, 2019
Revenue from Contract with Customer [Abstract]  
Summary of Revenue from Contracts with Customers
The following table summarizes revenue from contracts with customers for the three and nine months ended September 30, 2019 and 2018:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands)
2019
 
2018
 
2019
 
2018
U.S. Omnipod
$
109,464

 
$
81,970

 
$
293,641

 
$
230,289

International Omnipod
67,753

 
50,214

 
187,377

 
117,127

Total Diabetes Revenue
177,217

 
132,184

 
481,018

 
347,416

Drug Delivery
14,898

 
18,892

 
47,788

 
51,500

Total
$
192,115

 
$
151,076

 
$
528,806

 
$
398,916


Schedule of Revenue from Major Customers
Revenue for customers comprising more than 10% of total revenue were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,


2019
 
2018
 
2019
 
2018
Amgen, Inc.
*
 
12%
 
*
 
13%
Ypsomed
*
 
*
 
*
 
11%
Cardinal Health Inc. and affiliates
11%
 
12%
 
11%
 
12%
* Represents less than 10% of consolidated revenue.
Summary of Deferred Revenue
Deferred revenue related to unsatisfied performance obligations was included in the following consolidated balance sheet accounts in the amounts shown:
 
 
As of
(in thousands)
 
September 30, 2019
 
December 31, 2018
Accrued expenses and other current liabilities
 
$
2,007

 
$
1,184

Other liabilities
 
1,011

 
931

Total deferred revenue
 
$
3,018

 
$
2,115

 
 
 
 
 

Summary of Contract Acquisition Costs
Contract acquisition costs, representing capitalized commission costs related to new customers, net of amortization, were included in the following consolidated balance sheet accounts in the amounts shown:
 
 
As of
(in thousands)
 
September 30, 2019
 
December 31, 2018
Prepaid expenses and other current assets
 
$
9,006

 
$
7,277

Other assets
 
19,282

 
15,988

Total capitalized contract acquisition costs, net
 
$
28,288

 
$
23,265